The Food and Drug Administration (FDA) quietly updated the Emergency Use Authorization (EUA) for the Novavax COVID-19 vaccine.
This decision comes despite the official end of the Public Health Emergency nearly five months ago, as declared by the Centers for Disease Control and Prevention (CDC). The FDA’s action raises questions about its authority to approve an EUA when there is no longer a public health emergency.
The FDA’s website reveals on October 3, the agency amended the EUA for the Novavax COVID-19 Vaccine, Adjuvanted, to include the 2023-2024 formula. This updated vaccine now includes the spike protein from the SARS-CoV-2 Omicron variant lineage XBB.1.5.
Interestingly, the original monovalent version of the Novavax COVID-19 Vaccine, Adjuvanted, is no longer authorized for use in the United States.
🚨October 3, 2023🚨
While everyone is distracted by the feckless speaker it's a perfect time to issue an Emergency Use Authorization (EUA) for NOVAVAX.
Since there is no emergency anymore but they need to keep lining the elitists pockets and killing people.
I Present the… pic.twitter.com/5J56erANKO— Ted (@ted_macie) October 3, 2023
The updated Novavax vaccine is authorized for use in individuals aged 12 years and older. For those previously vaccinated with any COVID-19 vaccine, one dose of the updated Novavax vaccine is recommended at least two months after the last dose of the original vaccine.
For those not previously vaccinated, two doses of the updated vaccine are administered three weeks apart. Immunocompromised individuals may receive additional doses at the discretion of their healthcare provider.
This development coincides with the Biden administration’s decision to resume offering “at-home” COVID test kits. After halting taxpayer-funded distribution on June 1, 2023, each family can now receive up to four free tests per person.
This move follows Biden’s expenditure of $600 million to acquire 200 million tests.
The FDA’s quiet update of the Novavax vaccine’s EUA has sparked debate among health professionals. Some are questioning the sudden rise in excess mortality and the discovery of mysterious white fibrous clots in 50% of cadavers, as reported by travel embalmer Richard Hirschman.
Pfizer & Moderna COVID-19 mRNA Vaccines have been implicated in the highest rate of young people’s deaths in three years, with a 42% excess mortality in 0-24 year olds.
NOVAVAX JUST GIVEN A RENEWED SLOP AT THE TROUGH BY THE AGENCY FORMERLY KNOWN AS FDA
THE BIOWEAPON MADE FROM MOTH CELL DNA & ADJUVANTED WITH POISONOUS SAPONIN, to "irritate the immune system" into action
View & subscribe to my work on Apeel, the Bioweapons, & The Great Reset at… pic.twitter.com/G8WkY3qmFH
— DR JANE RUBY (@RealDrJaneRuby) October 5, 2023
Despite these concerns, the federal government continues to fuel COVID-19 hysteria through widespread testing and EUA vaccine authorizations. The FDA’s ability to approve an EUA when there is no longer an emergency, according to the CDC, left many puzzled.
A letter published on FDA.gov reveals that the Secretary of the Department of Health and Human Services (HHS) determined there is a public health emergency, or a significant potential for one, that affects national security or the health and security of U.S. citizens living abroad.
The FDA’s quiet update of the Novavax vaccine’s EUA raises questions about its authority and the ongoing response to the COVID-19 pandemic. As more data becomes available and health professionals voice their concerns, it is crucial to maintain transparency and accountability in our public health institutions.
